Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 26, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on January 24, 2006:
- Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 2,275 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- The company was advised of these transactions on January 25, 2006.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b). No other risks, contingencies, or unusual items are discussed in this text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to and after the January 24, 2006 transfer.
- Confirm the specific number of shares allocated to each participant in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.
- Check subsequent filings for any additional director share transactions during the same quarter.